Compare Novo Nordisk A/S (NVO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SiTime Corporation — how do they compare? Novo Nordisk A/S trades at $44.8 (market cap $200.69B), while SiTime Corporation trades at $588 (market cap $18.03B). The key difference: Novo Nordisk A/S is far larger — about 11.1× SiTime Corporation's market cap, and Novo Nordisk A/S pays a 3.98% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| NVO | SITM | |
|---|---|---|
Market Cap | $200.69B | $18.03B |
Sector | Health | Technology |
52-Week High | $63.98 | $901.60 |
52-Week Low | $35.29 | $245.57 |
Enterprise Value | $215.49B | $17.43B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SITM trades at $598.95, down 2.15% today, but maintains strong analyst support with 9 unanimous buy ratings and a $863.33 consensus price target representing 44% upside. The stock shows bullish technical signals despite recent weakness, with support at $584 and resistance at $627. Recent Q2 2026 earnings beat expectations with $2.34 EPS versus $1.95 expected, driven by 127% revenue growth and AI infrastructure demand.
The outlook remains positive with Q3 2026 guidance pointing to substantial growth following the Renesas acquisition. Key risks include high valuation multiples (P/E 999, P/S 34) and negative 2025 net income, though 2026 projections show profitability improvement. Institutional buying, including California State Teachers' 73,098.9% stake increase, supports the growth narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
